Don't miss an issue! Renew/subscribe for FREE today.
×
Medit Advertisement ×

BioHorizons biologics plus IntraSpin L-PRF

Posted on March 18, 2019

IDS 2019 Highlight

BioHorizons Camlog is adding the innovative IntraSpin® System from Intra-Lock® to its comprehensive portfolio of regenerative biomaterials. The IntraSpin® System is designed to obtain autologous leukocyte platelet-rich fibrin (L-PRF®) fibrin matrices and ensures good material biocompatibility. It is manufactured in Germany and has both CE approval as a Class IIa medical device and FDA approval for the American market.

What is L-PRF®?

By means of the L-PRF® technique, certain constituents and signaling substances can be released from autologous blood, which are reintroduced into the wound area to promote natural wound and tissue healing. The therapy is 100% natural and additive-free. Natural growth factors present in the patient´s body are concentrated when using L-PRF®. Making use of this autohemotherapy, the patient´s own concentrated platelets and other key blood cells are simply re-introduced into the site of the surgical procedure. As a result, the body´s own constituents are used to release powerful healing proteins and create a scaffold for healing.

The combination of this minimally invasive procedure with the proven products from BioHorizons® biologics promotes and accelerates soft tissue and bone regeneration, as scientific studies clearly show. As Professor Nelson R. Pinto once put it: “L-PRF®, a human living tissue that challenges the paradigm of osseointegration and tissue regeneration. What we thought impossible yesterday, could be routine tomorrow with L-PRF®

and natural guided regeneration.”

Indications and clinical application

In the last few years, interest and research in this topic has piqued. Science has delivered a wealth of new information on the mechanisms underlying the growth-factor processes of osseointegration and tissue regeneration, and has investigated the most suitable therapy concepts in each situation. Supplemented and updated information on therapy concepts are in the latest issue of "Guidelines for the use of L-PRF®", written by experts in the field of L-PRF®, in order to facilitate compilation of the most effective therapy concepts.1

Worldwide focus on science and education

BioHorizons Camlog is focusing on high-level education and a strong scientific basis for the application of L-PRF®. In 2019, the clinical master BioHorizons L-PRF® course in Italy with Prof. Testori – as well as CAMLOG’s and Rocker & Rocker GmbH courses in Hamburg, Frankfurt, Dusseldorf, Munich are great examples of BioHorizons Camlog continuous educational commitment. For worldwide distribution, BioHorizons Camlog will resort to its subsidiary and distributor network. In the German, Austrian and Swiss markets, distribution of the IntraSpin® System will be handled by Rocker & Rocker GmbH for Camlog. "Working together with Robin Rocker and his team, we have an ideal partner with many years of experience in the distribution of autologous blood products at our side," said Martin

Lugert, Managing Director of Camlog DACH. "I am delighted that the IntraSpin® system gives our customers access to the safe and fast reprocessing of autologous L-PRF® products".

As part of Henry Schein's Global Dental Surgical Group (GDSG), BioHorizons and Camlog work closely together to expand their combined global market position. The products of Intra-Lock®, also part of GDSG, complement the product range of BioHorizons and Camlog with innovative technologies such as the IntraSpin® System.

About BioHorizons and Camlog

BioHorizons and Camlog are leading suppliers of premium dental implant systems, restorative components, a comprehensive line of biologics products and digital solutions. They are committed to developing evidence-based and scientifically proven products, as well as continuous education according to highest standards.

Headquartered in the U.S. and Europe, respectively, BioHorizons and CAMLOG’s geographic positions allow them to efficiently serve direct subsidiaries in the Americas and Western Europe, as well as their entire distribution network in more than 80 countries around the world. The companies are part of Henry Schein, Inc., a solutions company for health care professionals powered by a network of people and technology. With more than 18,000 Team Schein Members worldwide, Henry Schein’s network of trusted advisors provides over 1 million customers globally with more than 300 valued solutions that improve operational success and clinical outcomes. The Company’s Business, Clinical, Technology, and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites. For more information, visit www.biohorizons.com, www.camlog.com and www.henryschein.com.

References

1. Nelson R. Pinto1, Andy Temmerman2, Ana B. Castro2, Simone Cortellini2, Wim Teughels2, & Marc Quirynen2 University of the Andes,

Department of Periodontics and Implant Dentistry, Faculty of Dentistry, Santiago, Chile and Catholic University of Leuven / University

Hospitals Leuven, Department of Oral Health Sciences, Periodontology, Leuven, Belgium. 







© 2021 AEGIS Communications | Privacy Policy